web analytics
Pharmaceutical formulation challenges met with scientific expertise | Velesco Pharma

Drug Formulation Challenge 5

Formulation Development of Active Pharmaceutical Ingredient (API)


Our client requested formulation development for several different lots of drug product material, all displaying different characteristics, which impacted the solubility of each.


Velesco solution:

  • A pharmaceutical formulation was successfully developed for the first lot of material using HP-γ-CD. The next lot we received was not stable in HP-γ-CD however was successfully formulated in SBE-β-CD with pH titration.  The next two lots were also successful in SBE-β-CD with subtle variations on the formulation procedure and pH titration.  A common vehicle was identified for all four lots and stability of one of the lots was confirmed for six months at 5°C.
  • Velesco explored a series of stability testing experiments and paths to determine the cause of the varying solubility and physical stability of different lots of the compound.  Using previous drug formulation experience and knowledge of the compound, Velesco was able to fine-tune each formulation to achieve the targeted concentration and pH within tight time lines. 
  • Velesco identified suitable vehicles for both intravenous and intrathecal routes of administration.
  • Clinical supplies were prepared for 14 different toxicology studies. Formulations have been well tolerated by animals and studies have been successful to date. 
  • Velesco improved the scalability of the drug formulation in preparation for future larger scale manufactures.

Back to drug formulation development case studies

News and Events

Pace® Life Sciences Acquires Velesco Pharmaceutical Services, Expanding Capabilities in Drug Development Services

Read the Press Release!

Dave Barnes, Ph.D. CEO/CSO is a featured speaker for the webinar Topical Formulation: Selection of Excipients and Better Process Understanding for Success in Commercial Manufacturing. Webinar recording available now.

View Recording!

Newly Acquired DEA Analytical Laboratory License. We are licensed to use schedules 2, 2N, 3, 3N, 4, and 5.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gerry Cox, Founder and Chief Operating Officer at Velesco Pharmaceutical Services.

Roundtable: M&A trends in CDMO - Molecule to Market

New Velesco Pharma clinical manufacturing facility begins operations.

Read the press release here.

Lisa Crandall, MS, and Peter Angus, PhD, spoke with Pharmaceutical Technology about the best practices in stability testing.

Read the interview here.

Velesco has expanded our analytical facilities in a new Wixom, Michigan location with the help of the Bank of Ann Arbor Technology Industry Group.

Read the press release here.

CEO Dave Barnes has been published in a new Pharmoutsourcing article on Clinical Trial Materials and Manufacturing!

1 new job postings! Careers

Velesco's work published

Formulation Development & Manufacturing:
Using a Single Provider Reduces Costs & Risk
Read it here.

Follow Velesco

LinkedIn IN Icon 25px Google+ Follow VelescoPharma on Twitter FB FindUsOnFacebook 100